Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

Parkinson's Disease Dementia (PDD)

A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Parkinson's Disease Dementia



Booth Gardner Parkinson's Care Center is conducting a study to evaluate the clinical effects, safety and tolerability of ATH-1017 in subjects with Parkinson's disease dementia (PDD). ATH-1017 is an experimental treatment for Alzheimer's disease (AD) and Parkinson's disease dementia (PDD), formulated as a sterile solution for subcutaneous (SC) injection.

Currently enrolling

Who may be eligible to participate?

Male and female, 40 to 85 years with a confirmed diagnosis of probable idiopathic Parkinson's disease or probable LBD for at least 1 year.

What does participation involve?

  • The study will be conducted on an outpatient basis.
  • During the double-blind treatment period, clinic visits will take place on Day 1 and at Weeks 2, 6, 12, 16, 20, and 26, with a safety follow-up visit at Week 30.
  • Study drug/placebo will be administered by subcutaneous (SC) injection once daily, preferably during daytime.
  • Participants will receive 1 syringe/day of one of the following:
    • 70 mg/ml of ATH-1017
    • 40 mg/ml of ATH-1017
    • placebo
IRB Protocol Number
Principal Investigator(s)
Daniel Burdick, MD

Clinical Trial Categories

  • Parkinson's Disease
EvergreenHealth Research Services at 425-899-5385


  • EvergreenHealth Clinical Trials
    12039 NE 128th Street, Suite 300
    Kirkland, WA 98034
    Main: 425-899-5385

Contact Us

Call us at (425) 899-5385 or use our online information request form.

Online Form